183 related articles for article (PubMed ID: 23481354)
1. Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".
Rytelewski M; Ferguson PJ; Maleki Vareki S; Figueredo R; Vincent M; Koropatnick J
Mol Ther Nucleic Acids; 2013 Mar; 2(3):e78. PubMed ID: 23481354
[TBL] [Abstract][Full Text] [Related]
2. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger.
Berg RW; Ferguso PJ; DeMoor JM; Vincen MD; Koropatnick J
Curr Drug Targets; 2002 Aug; 3(4):297-309. PubMed ID: 12102601
[TBL] [Abstract][Full Text] [Related]
3. Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs.
Jason TL; Berg RW; Vincent MD; Koropatnick J
Gene Expr; 2007; 13(4-5):227-39. PubMed ID: 17605297
[TBL] [Abstract][Full Text] [Related]
4. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.
Rytelewski M; Tong JG; Buensuceso A; Leong HS; Maleki Vareki S; Figueredo R; Di Cresce C; Wu SY; Herbrich SM; Baggerly KA; Romanow L; Shepherd T; Deroo BJ; Sood AK; Chambers AF; Vincent M; Ferguson PJ; Koropatnick J
Mol Oncol; 2014 Dec; 8(8):1429-40. PubMed ID: 24974076
[TBL] [Abstract][Full Text] [Related]
5. Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed.
Di Cresce C; Figueredo R; Ferguson PJ; Vincent MD; Koropatnick J
J Pharmacol Exp Ther; 2011 Sep; 338(3):952-63. PubMed ID: 21673071
[TBL] [Abstract][Full Text] [Related]
6. ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines.
Jason TL; Figueredo R; Ferguson PJ; Vincent MD; Berg RW; Koropatnick J
DNA Cell Biol; 2008 May; 27(5):229-40. PubMed ID: 18358073
[TBL] [Abstract][Full Text] [Related]
7. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
8. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E
J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
10. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
[TBL] [Abstract][Full Text] [Related]
11. Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.
Ferguson PJ; Collins O; Dean NM; DeMoor J; Li CS; Vincent MD; Koropatnick J
Br J Pharmacol; 1999 Aug; 127(8):1777-86. PubMed ID: 10482907
[TBL] [Abstract][Full Text] [Related]
12. Analysis of DNA repair and recombination responses in mouse cells depleted for Brca2 by SiRNA.
Lee SA; Baker MD
DNA Repair (Amst); 2007 Jun; 6(6):809-17. PubMed ID: 17336596
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
[TBL] [Abstract][Full Text] [Related]
14. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
16. Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.
Pandyra AA; Berg R; Vincent M; Koropatnick J
J Pharmacol Exp Ther; 2007 Jul; 322(1):123-32. PubMed ID: 17452420
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
18. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Berg RW; Ferguson PJ; Vincent MD; Koropatnick DJ
Cancer Gene Ther; 2003 Apr; 10(4):278-86. PubMed ID: 12679800
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
Flynn J; Berg RW; Wong T; van Aken M; Vincent MD; Fukushima M; Koropatnick J
Mol Cancer Ther; 2006 Jun; 5(6):1423-33. PubMed ID: 16818500
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis.
De Toni EN; Ziesch A; Rizzani A; Török HP; Hocke S; Lü S; Wang SC; Hucl T; Göke B; Bruns C; Gallmeier E
Oncotarget; 2016 Feb; 7(8):9477-90. PubMed ID: 26843614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
